Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat
- PMID: 29155273
- DOI: 10.1016/j.neuropharm.2017.11.026
Mu-opioid peptide (MOP) and nociceptin/orphanin FQ peptide (NOP) receptor activation both contribute to the discriminative stimulus properties of cebranopadol in the rat
Abstract
The novel potent analgesic cebranopadol is an agonist at nociceptin/orphanin FQ peptide (NOP) and classical opioid receptors, with the highest in-vitro activity at NOP and mu-opioid peptide (MOP) receptors, and somewhat lower activity at kappa-opioid peptide (KOP) and delta-opioid peptide (DOP) receptors. We addressed the question of which of these pharmacological activities contribute to the stimulus properties of cebranopadol using a rat drug discrimination procedure. First, cebranopadol was tested in generalization tests against a morphine cue, including receptor-specific antagonism. Second, cebranopadol was established as a cue, and MOP, NOP, KOP and DOP receptor-selective agonists were tested in generalization tests. Third, cebranopadol in combination with receptor-selective antagonists was tested against the cebranopadol cue. Cebranopadol generalized to the morphine cue. Full generalization was only seen at clearly supra-analgesic doses. The effect of cebranopadol was reduced by naloxone, but was enhanced by the NOP receptor antagonist J-113397. In cebranopadol-trained rats, cebranopadol as well as morphine produced generalization. A NOP receptor agonist did not, while a DOP receptor agonist and a KOP receptor agonist weakly generalized to the cebranopadol cue. Conversely, generalization of cebranopadol was reduced by naloxone and J-113397, but not by a DOP or a KOP receptor antagonist. These results suggest a contribution of MOP receptor activity and a relative lack of contribution of DOP and KOP receptor activity to cebranopadol's stimulus properties. The findings regarding the contribution of NOP receptor activity were equivocal, but interestingly, the morphine-like stimulus property of cebranopadol appears to be reduced by its intrinsic NOP receptor activity.
Keywords: DOP receptor; Drug discrimination; KOP receptor; MOP receptor; NOP receptor; Stimulus property.
Copyright © 2017 Elsevier Ltd. All rights reserved.
Similar articles
-
Synergistic interaction between the agonism of cebranopadol at nociceptin/orphanin FQ and classical opioid receptors in the rat spinal nerve ligation model.Pharmacol Res Perspect. 2018 Nov 28;6(6):e00444. doi: 10.1002/prp2.444. eCollection 2018 Dec. Pharmacol Res Perspect. 2018. PMID: 30519474 Free PMC article.
-
Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.Eur J Pharmacol. 2018 Aug 5;832:90-95. doi: 10.1016/j.ejphar.2018.05.005. Epub 2018 May 9. Eur J Pharmacol. 2018. PMID: 29753041
-
Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.J Pharmacol Exp Ther. 2014 Jun;349(3):535-48. doi: 10.1124/jpet.114.213694. Epub 2014 Apr 8. J Pharmacol Exp Ther. 2014. PMID: 24713140
-
Cebranopadol : a first-in-class potent analgesic agent with agonistic activity at nociceptin/orphanin FQ and opioid receptors.Expert Opin Investig Drugs. 2015 Jun;24(6):837-44. doi: 10.1517/13543784.2015.1036985. Epub 2015 Apr 12. Expert Opin Investig Drugs. 2015. PMID: 25865744 Review.
-
Opioid Receptors in Immune and Glial Cells-Implications for Pain Control.Front Immunol. 2020 Mar 4;11:300. doi: 10.3389/fimmu.2020.00300. eCollection 2020. Front Immunol. 2020. PMID: 32194554 Free PMC article. Review.
Cited by
-
Cebranopadol reduces cocaine self-administration in male rats: Dose, treatment and safety consideration.Neuropharmacology. 2020 Aug 1;172:108128. doi: 10.1016/j.neuropharm.2020.108128. Epub 2020 May 8. Neuropharmacology. 2020. PMID: 32389751 Free PMC article.
-
BU10038 as a safe opioid analgesic with fewer side-effects after systemic and intrathecal administration in primates.Br J Anaesth. 2019 Jun;122(6):e146-e156. doi: 10.1016/j.bja.2018.10.065. Epub 2019 Mar 1. Br J Anaesth. 2019. PMID: 30916003 Free PMC article.
-
A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.Sci Transl Med. 2018 Aug 29;10(456):eaar3483. doi: 10.1126/scitranslmed.aar3483. Sci Transl Med. 2018. PMID: 30158150 Free PMC article.
-
Effects of Cebranopadol on Cocaine-induced Hyperactivity and Cocaine Pharmacokinetics in Rats.Sci Rep. 2020 Jun 9;10(1):9254. doi: 10.1038/s41598-020-66250-z. Sci Rep. 2020. PMID: 32518276 Free PMC article.
-
Opioid Crisis-An Emphasis on Fentanyl Analogs.Brain Sci. 2020 Jul 27;10(8):485. doi: 10.3390/brainsci10080485. Brain Sci. 2020. PMID: 32726995 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials